RxDoctor Payments Data

Anna Morgan, MD

Internal Medicine · Mount Pleasant, SCNPI 1215010640

Payments from drug & device makers

$474in general payments, 2019–2025

Across 10 payments — averaging $47.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$221
  • Amgen$139
  • Mallinckrodt Hospital Products Inc.$32
  • Astellas Pharma US Inc$24
  • Daiichi Sankyo Inc.$22
  • Pfizer$20
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$474100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$474 in reported general payments places this provider in the 55th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$102,485
Medicare patients
284
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$85,776
EliquisApixaban50$43,690
TrulicityDulaglutide35$34,776
MounjaroTirzepatide24$31,800
JardianceEmpagliflozin18$29,383
XareltoRivaroxaban16$25,092
LinzessLinaclotide17$13,872
MyrbetriqMirabegron12$10,661
Breo ElliptaFluticasone/Vilanterol19$10,189
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,410
Gabapentin114$3,620
Rosuvastatin Calcium253$3,462
Atorvastatin Calcium293$3,031
Almotriptan Malate12$2,805
SynthroidLevothyroxine Sodium35$2,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$221$66,57659 claims
PfizerEliquis$20$43,69050 claims
Astellas Pharma US IncMyrbetriq$24$10,66112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Mount Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →